MBTPS1 and interstitial lung disease: LPA antagonists are already in clinical development [79], the direct thrombin inhibitor dabigatran etexilate is tested in preclinical fibrosis models [38, 80] and in patients with scleroderma-associated interstitial lung disease [81], and blocking S1P signalling is also considered as an attractive strategy in fibrotic disorders [82].